Search Within

Michael John Mauro

Formats
  1. Meeting Abstract (188)
  2. Journal Article (67)
  3. Review (8)
  4. Correspondence (4)
  5. Research Letter (3)
  6. Book Section (2)
  7. Editorial (2)
  8. Guidelines (2)
Groups
  1. Adult Leukemia (276)
  2. Center for Hematologic Malignancies (276)
  3. Department of Medicine (276)
  4. Hematologic Malignancies, Division of (276)
  5. Biostatistics Service (10)
  6. Epidemiology and Biostatistics (10)

More Groups

People
  1. Raajit Rampal (12)
  2. Ellin Berman (8)
  3. Eytan Stein (8)
  4. Martin Tallman (7)
  5. Amber King (6)
  6. Andriy Derkach (6)

More People

Years
  1. 2025 (7)
  2. 2024 (17)
  3. 2023 (26)
  4. 2022 (33)
  5. 2021 (21)
  6. 2020 (26)

More Years

Publications
  1. Blood (97)
  2. Clinical Lymphoma, Myeloma and Leukemia (44)
  3. Journal of Clinical Oncology (22)
  4. Haematologica (21)
  5. Leukemia (12)
  6. American Journal of Hematology (8)

More Publications

Publishers
  1. American Society of Hematology (101)
  2. Elsevier Inc. (47)
  3. American Society of Clinical Oncology (22)
  4. Ferrata Storti Foundation (21)
  5. Nature Publishing Group (13)
  6. John Wiley & Sons (8)

More Publishers

Results (276)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs
    Journal Article

    Réa, D.; Mauro, M. J.; Boquimpani, C.; Minami, Y.; Lomaia, E.; Voloshin, S.; Turkina, A.; Kim, D. W.; Apperley, J. F.; Abdo, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Serum antibody response in patients with philadelphia-chromosome positive or negative myeloproliferative neoplasms following vaccination with SARS-CoV-2 spike protein messenger RNA (mRNA) vaccines
    Research Letter

    Kozak, K. E.; Ouyang, L.; Derkach, A.; Sherman, A.; McCall, S. J.; Famulare, C.; Chervin, J.; Daley, R. J.; Morjaria, S.; Mauro, M. J.; more...
    Leukemia (2021)

    Fulltext@MSK | Save
  • Using PROMIS-preference (PROPr) scores to measure changes in quality of life after tyrosine kinase inhibitor discontinuation
    Meeting Abstract

    Winn, A.; Atallah, E.; Lin, L.; Thompson, J.; Moore, J.; Larson, R.; Cortes, J.; Mauro, M.; Pinilla, J.; Flynn, K.
    Quality of Life Research (2021)

    Fulltext@MSK | Save
  • OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON)
    Meeting Abstract

    Cortes, J. E.; Apperley, J.; Lomaia, E.; Moiraghi, B.; Sutton, M. U.; Pavlovsky, C.; Chuah, C.; Sacha, T.; Lipton, J. H.; Schiffer, C.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: A randomized, open-label phase 2 clinical trial
    Journal Article

    Cortes, J.; Apperley, J.; Lomaia, E.; Moiraghi, B.; Undurraga Sutton, M.; Pavlovsky, C.; Chuah, C.; Sacha, T.; Lipton, J. H.; Schiffer, C. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Asciminib provides durable responses and a favorable safety profile in patients with chronic myeloid leukemia (CML) in chronic phase (CP) with the T315I mutation in a phase 1 study
    Meeting Abstract

    Cortes, J. E.; Hughes, T. P.; Mauro, M. J.; Hochhaus, A.; Réa, D.; Goh, Y. T.; Janssen, J. J. W. M.; Heinrich, M. C.; Talpaz, M.; Etienne, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • ASCEMBL phase 3 health-related quality of life (HRQL) comparison of asciminib and bosutinib for patients with chronic myelogenous leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors (TKI)
    Meeting Abstract

    Mauro, M. J.; Boquimpani, C.; Rea, D.; Hochhaus, A.; Maheshwari, V. K.; Allepuz, A.; Patwardhan, P.; Wu, Y.; DeRosa, M.; Minami, Y.
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Effect of comorbidities on response outcomes with first-line tyrosine kinase inhibitors (TKIs), dasatinib versus imatinib, in patients with chronic myeloid leukemia in chronic phase (CML-CP): Exploratory post hoc analysis of DASISION
    Meeting Abstract

    Breccia, M.; Mauro, M.; Jabbour, E.; Saglio, G.; Jiménez-Velasco, A.; le Coutre, P.; DeGutis, I.; Khan, W.; Sy, O.; Swanink, R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON)
    Meeting Abstract

    Cortes, J. E.; Apperley, J. F.; Lomaia, E.; Moiraghi, B.; Sutton, M. U.; Pavlovsky, C.; Chuah, C.; Sacha, T.; Lipton, J. H.; McCloskey, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Health care resource utilization (HCRU) with asciminib and bosutinib among patients with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs): Results from the multicenter, open-label phase 3 ASCEMBL trial
    Meeting Abstract

    Smith, B. D.; Cortes, J. E.; Rea, D.; Mauro, M. J.; Patwardhan, P.; Maegawa, R.; Zacker, C.; Corbin, R.; Keeping, S.; Sasaki, K.
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save